Results 131 to 140 of about 77,990 (218)

The TCR and LCK: foundations for T-cell activation and therapeutic innovation. [PDF]

Front Immunol
Woessner NM, Uleri V, Stepanek O, Minguet S.   +3 more
europepmc   +1 more source

Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing. [PDF]

Hematology Am Soc Hematol Educ Program
Bonini C.
europepmc   +1 more source

Ultrasmall Au10–12 Nanoclusters: A Novel Platform for 223Ra‐Targeted Tumor α‐Therapy

Exploration, EarlyView.
Encapsulating 223Ra in Au10‐12 nanoclusters and functionalizing them with RGD peptides enables targeted α‐therapy and immune microenvironment remodeling in non‐osseous tumors like triple‐negative breast cancer. This study establishes a foundational framework for novel 223Ra‐labeled α‐radiopharmaceuticals and shows strong potential for clinical ...
Yifei Jiang, Huizhen Yang, Guoping Jia, Wangxi Hai, Rongyi Huang, Peng Wang, Min Zhang, Danni Li, Yizhou Chen, Xiao Li, Biao Li, Chunfu Zhang   +11 more
wiley   +1 more source

Neurological implications of chimeric antigen receptor-T cell therapy. [PDF]

BMJ Neurol Open
Raffoul DG, Roos I, Mulazzani M, Anderson MA, Monif M, Garber J, van der Walt A, Massey J, Kuznetsova V, Nesbitt C, Dowling M, Ruderman I, Lasocki A, Tam CS, Harrison SJ, Kalincik T.   +15 more
europepmc   +1 more source

Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status

International Journal of Cancer, EarlyView.
What's New? TRIM25 is known for its role in antiviral immunity and association with poor prognosis in various cancers. This study reveals an association between high TRIM25 expression and Merkel cell polyomavirus positivity in Merkel cell carcinoma.
Klaus W. Fagerstedt, Sami Kilpinen, Johanna Arola, Benjamin Z. Sundqvist, Tom Böhling, Leif C. Andersson, Harri Sihto   +6 more
wiley   +1 more source

Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T. [PDF]

J Immunother Cancer
Wang N, Liu L, Zhang L, Li J, Wan Y, Li X, Chen X, Yin Z, Zhang A, Zhang X, Chen Y, Hu T, Zhang Y, Liu F, Zhu X, Yang W.   +15 more
europepmc   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry. [PDF]

J Neurooncol
Liu J, Abikenari M, Annagiri S, Ha JH, Nageeb G, Sjoholm MA, Velazhahan V, Medikonda R, Choi J, Li G, Lim M.   +10 more
europepmc   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

International Journal of Cancer, EarlyView.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang   +5 more
wiley   +1 more source

Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies. [PDF]

Front Med (Lausanne)
Khan A, Mujahid A, Tareen A, Amin A, Khan SR, Hadi DK, Raza A.   +6 more
europepmc   +1 more source